BioCryst Pharmaceuticals (NASDAQ: BCRX) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its peers? We will compare BioCryst Pharmaceuticals to similar businesses based on the strength of its dividends, earnings, profitability, valuation, institutional ownership, analyst recommendations and risk.

Volatility & Risk

BioCryst Pharmaceuticals has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals’ peers have a beta of 2.53, meaning that their average stock price is 153% more volatile than the S&P 500.

Institutional and Insider Ownership

84.7% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 5.6% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


This table compares BioCryst Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioCryst Pharmaceuticals -167.58% -123.16% -38.71%
BioCryst Pharmaceuticals Competitors -5,192.50% -162.92% -35.31%

Analyst Ratings

This is a breakdown of recent ratings and price targets for BioCryst Pharmaceuticals and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioCryst Pharmaceuticals 0 3 7 0 2.70
BioCryst Pharmaceuticals Competitors 909 3322 11808 237 2.70

BioCryst Pharmaceuticals presently has a consensus target price of $9.14, suggesting a potential upside of 68.07%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.50%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe BioCryst Pharmaceuticals is more favorable than its peers.

Valuation & Earnings

This table compares BioCryst Pharmaceuticals and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioCryst Pharmaceuticals $26.35 million -$55.14 million -8.50
BioCryst Pharmaceuticals Competitors $290.27 million $35.99 million 59.60

BioCryst Pharmaceuticals’ peers have higher revenue and earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


BioCryst Pharmaceuticals peers beat BioCryst Pharmaceuticals on 7 of the 13 factors compared.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company’s drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with's FREE daily email newsletter.